mRNA Platform Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases), by Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines), by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), by End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

7.30 billion

CAGR (2023-2028)

35.20%

Fastest Growing Segment

Self-Amplifying mRNA Segment

Largest Market

North America

Market Overview

Global mRNA Platform Market has valued at USD 7.30 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 35.20% through 2028. The mRNA (messenger RNA) platform is a cutting-edge technology in biotechnology and medicine that uses synthetic RNA molecules to convey genetic information and instructions to cells, allowing them to produce specific proteins. This technology has gained significant attention and success, particularly in vaccine development and the treatment of various diseases.  mRNA is a type of genetic material that normally carries instructions from DNA (the genetic code) to the cell's protein-making machinery (ribosomes). It serves as a temporary copy of a gene's instructions. In the mRNA platform, synthetic or modified mRNA molecules are designed to carry specific genetic instructions for producing a particular protein. Scientists can design and synthesize mRNA sequences with precise genetic information. This information can be customized for various purposes, such as producing therapeutic proteins or instructing the immune system to generate an immune response. In vaccine development, the mRNA platform is used to create mRNA vaccines. These vaccines contain mRNA molecules that encode a portion of the target pathogen, such as a viral protein or a unique antigen.

Beyond vaccines, the mRNA platform is used for therapeutic purposes. Researchers are exploring mRNA-based therapies for a wide range of conditions, including cancer, genetic disorders, autoimmune diseases, and allergies. In cancer immunotherapy, for example, mRNA is designed to instruct immune cells to target and attack cancer cells, harnessing the body's immune system to fight the disease. The COVID-19 pandemic accelerated the adoption of mRNA technology for vaccine development. The success of mRNA vaccines for COVID-19 generated enormous interest and investment in this technology, highlighting its potential in responding to emerging infectious diseases. mRNA technology's versatility allows for the development of vaccines and therapies for a wide range of diseases, including infectious diseases, cancer, genetic disorders, and autoimmune conditions. This adaptability makes it an attractive platform for addressing various medical challenges.

Key Market Drivers

Technological Advancements

Lipid Nanoparticle (LNP) Delivery Systems are crucial for delivering mRNA to cells efficiently. Advances in LNP design and formulation have improved the stability, delivery, and efficacy of mRNA vaccines and therapies. These advancements have played a pivotal role in the success of COVID-19 mRNA vaccines. Researchers have developed modified mRNA sequences with enhanced stability and reduced immunogenicity. This has extended the shelf life of mRNA vaccines and made them more suitable for distribution and storage. Codon optimization involves modifying the genetic code to improve protein expression. Researchers have been fine-tuning codon usage to enhance protein production, which is particularly important for therapeutic applications. Advances in synthetic biology techniques, such as CRISPR-Cas9, have facilitated the precise editing and manipulation of mRNA sequences. This technology has opened new possibilities for mRNA-based therapies targeting genetic diseases. Scalable and cost-effective manufacturing processes have been developed to meet the high demand for mRNA-based vaccines and therapies. These improvements in manufacturing have enabled rapid production during public health emergencies. Researchers have made progress in increasing the stability of mRNA vaccines at various temperature ranges, reducing the need for ultra-low-temperature storage and distribution. Next-Generation Sequencing (NGS) has enabled researchers to analyze mRNA sequences rapidly and accurately, facilitating the design of mRNA-based therapies tailored to specific targets.

Cap analogues are added to the beginning of mRNA sequences to mimic natural mRNA. This improves the translational efficiency of synthetic mRNA and increases its similarity to endogenous mRNA. Cell-free systems for mRNA production have been developed, allowing for more efficient and scalable synthesis of mRNA molecules for research and therapeutic purposes. Advancements in mRNA technology have enabled the development of personalized medicine approaches, where therapies are tailored to an individual's genetic profile. Adjuvants are substances added to vaccines to enhance the immune response. Research has focused on developing novel adjuvants specifically designed for mRNA-based vaccines. Innovations in intracellular delivery methods, such as electroporation and microneedle patches, have improved the efficient uptake of mRNA into target cells. Extensive research into mRNA formulation and stability has improved the ability to store and transport mRNA vaccines and therapies under various conditions. This factor will help in the development of the Global mRNA Platform Market.


Download Free Sample Report

Emerging Applications

 One of the most promising emerging applications is cancer immunotherapy. Researchers are developing mRNA-based cancer vaccines and therapies that stimulate the patient's immune system to target and destroy cancer cells. This approach offers a personalized and potentially more effective treatment for various types of cancer. While mRNA vaccines have already demonstrated their effectiveness against infectious diseases like COVID-19, ongoing research aims to develop mRNA-based vaccines for other infectious diseases, such as influenza, HIV, Zika virus, and respiratory syncytial virus (RSV). The adaptability of mRNA technology makes it well-suited for responding to emerging pathogens. mRNA technology is being explored for the treatment of rare genetic disorders caused by specific mutations. By delivering modified mRNA to correct genetic defects, researchers aim to provide targeted and personalized therapies for patients with conditions like cystic fibrosis and certain inherited metabolic disorders. mRNA technology has potential applications in regenerative medicine by guiding the differentiation of stem cells into specific cell types for tissue repair and replacement. This could be particularly valuable for treating degenerative diseases and injuries. mRNA can be used to deliver gene-editing tools like CRISPR-Cas9 to target and modify specific genes. This technology holds promise for treating genetic diseases and correcting genetic mutations. Researchers are exploring mRNA to replace or supplement deficient proteins in patients with genetic or acquired protein deficiencies. This approach can be used to treat conditions like hemophilia and certain enzyme deficiencies.

mRNA technology is being investigated for the development of therapies for autoimmune diseases. By modulating the immune response, mRNA-based treatments may help regulate and control autoimmune conditions. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments. The ability to customize mRNA-based therapies based on an individual's genetic profile is a significant driver in personalized medicine. Tailoring treatments to a patient's unique genetic makeup can improve treatment outcomes. Beyond healthcare, mRNA technology has applications in biotechnology, including the production of recombinant proteins and enzymes. It also holds potential for use in other fields, such as agriculture and industrial biotechnology. This factor will pace up the demand of the Global mRNA Platform Market.

Growth in Pandemic Response and Vaccines

mRNA technology allowed for the rapid development of COVID-19 vaccines. Within a remarkably short timeframe, companies like Pfizer-BioNTech and Moderna developed, tested, and received emergency use authorization for mRNA-based COVID-19 vaccines. This speed of development was crucial in controlling the pandemic. mRNA vaccines have demonstrated high levels of efficacy against COVID-19, contributing to their rapid adoption and widespread use. The effectiveness of these vaccines in preventing severe illness and transmission has been a strong driver of demand. mRNA technology is well-suited to adapt to new virus variants. The flexibility of mRNA allows for the quick modification of vaccine candidates to address emerging variants of the virus, addressing concerns about vaccine effectiveness in the face of viral mutations. The scalability and rapid production capabilities of mRNA vaccines have supported global vaccination efforts. Governments, international organizations, and healthcare systems have sought to secure mRNA vaccines to protect their populations, driving demand for increased production.

The pandemic highlighted the importance of being prepared for emerging infectious diseases. Governments and organizations worldwide have recognized the potential of mRNA technology to respond quickly to future pandemics and have invested in building infrastructure and capabilities. The success of mRNA-based COVID-19 vaccines attracted substantial investment and funding from both the public and private sectors. This financial support has accelerated research and development efforts and expanded the mRNA platform's applications. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), collaborated closely with mRNA technology developers to expedite the regulatory approval process during public health emergencies. The effectiveness and safety of mRNA COVID-19 vaccines have contributed to public confidence in this technology. As a result, there has been increased acceptance of mRNA-based vaccines and therapies. The success of mRNA vaccines has spurred further research and development in the field. Researchers and companies are exploring the potential of mRNA technology for a wide range of applications, including vaccines and therapies for other infectious diseases. The global response to the pandemic has involved collaboration between countries, pharmaceutical companies, and research institutions. This collaboration has accelerated the sharing of knowledge and expertise in mRNA technology. This factor will accelerate the demand of the Global mRNA Platform Market.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, which refers to the reluctance or refusal to get vaccinated, can slow down the adoption of mRNA vaccines. This can impede efforts to achieve herd immunity and control the spread of infectious diseases. Misinformation, often spread through social media and other channels, can lead to misconceptions and false beliefs about mRNA vaccines. This can include concerns about vaccine safety, efficacy, and long-term effects. Misinformation can undermine public confidence in vaccines and deter individuals from getting vaccinated. Lower vaccine coverage due to hesitancy and misinformation can lead to ongoing outbreaks of preventable diseases, including potentially deadly infectious diseases like COVID-19. These outbreaks can strain healthcare systems, result in increased morbidity and mortality, and have economic and societal consequences. High levels of vaccine hesitancy can hinder efforts to achieve herd immunity, which is essential for protecting vulnerable populations who cannot receive vaccines due to medical reasons. Herd immunity is crucial for controlling the spread of contagious diseases within communities. Misinformation and hesitancy can disrupt vaccination campaigns and lead to lower vaccine uptake rates, particularly during public health emergencies like pandemics. Widespread vaccine hesitancy and the propagation of vaccine misinformation can erode public trust in public health institutions, healthcare providers, and government recommendations. This erosion of trust can extend to other public health measures, making it more challenging to implement effective disease control strategies.

Variants and Adaptability

Many infectious pathogens, particularly viruses, can undergo genetic mutations that result in the emergence of new variants or strains. These variants can have different properties, including increased transmissibility and resistance to immunity. Variants can pose a threat to public health by potentially leading to more severe disease or reduced vaccine effectiveness. The effectiveness of vaccines, including mRNA vaccines, can vary against different variants. Some variants may partially evade the immune response induced by existing vaccines. This challenges the ability of vaccines to provide broad and long-lasting protection against evolving pathogens. To maintain vaccine effectiveness, researchers and manufacturers need to adapt mRNA vaccines quickly to address emerging variants. This may involve modifying the mRNA sequence to encode the antigen(s) of the new variant. Rapid adaptation is critical during pandemics and outbreaks to ensure that vaccines remain effective. Regulatory agencies may need to provide streamlined approval processes for variant-adapted vaccines to expedite their availability during public health emergencies. Developing and gaining regulatory approval for variant-specific vaccines can be resource-intensive and time-consuming. Adapting mRNA vaccines to address new variants may require adjustments in the manufacturing process. Scaling up production to meet global demand for updated vaccines can be challenging.

Key Market Trends

Personalized Medicine

Advances in genomics and genetic testing have made it increasingly feasible to analyze an individual's genetic information quickly and affordably. This genetic profiling allows healthcare providers to identify genetic variations that may impact disease susceptibility and treatment responses. mRNA technology enables the development of targeted therapies that can be customized based on a patient's genetic profile. By designing mRNA sequences to address specific genetic variations or disease markers, researchers can create personalized treatments. In the context of cancer, personalized medicine was a notable application. Researchers were exploring mRNA-based cancer vaccines and therapies that target individualized tumor antigens. These therapies aim to harness the patient's immune system to target and destroy cancer cells specifically. Personalized mRNA therapies were being developed to address rare genetic diseases caused by specific mutations. By tailoring mRNA sequences to correct or compensate for these mutations, researchers were working to provide individualized treatments. mRNA vaccines can be customized to deliver allergen-specific immunotherapy for allergies. This approach offers the potential for more precise and effective allergy treatments tailored to each patient's allergens. mRNA technology allows for the monitoring of a patient's response to treatment by analyzing changes in gene expression. This information can be used to adjust and personalize treatment plans. Integrating pharmacogenomic data with mRNA-based therapies can help determine the most suitable medications and dosages for individual patients, reducing adverse effects and optimizing treatment outcomes.

Segmental Insights

Indication Insights

In 2022, the Global mRNA Platform Market largest share was held by Autoimmune Diseases segment and is predicted to continue expanding over the coming years.  Autoimmune diseases represent a significant medical challenge due to their complex and often poorly understood nature. Many autoimmune diseases have limited treatment options, and mRNA technology holds promise for developing innovative therapies to address unmet medical needs in this segment. mRNA technology can be used to modulate the immune system, making it an attractive approach for treating autoimmune diseases. By designing mRNA sequences to target specific immune responses, researchers can potentially suppress or regulate the immune system's harmful activities in autoimmune conditions. Autoimmune diseases often have variable manifestations and responses to treatment among patients. mRNA-based therapies can be customized to target specific autoimmune pathways or antigens, allowing for a personalized approach to treatment.

Usability Insights

In 2022, the Global mRNA Platform Market largest share was held by Therapeutic Vaccines segment and is predicted to continue expanding over the coming years. The COVID-19 pandemic had a significant impact on the mRNA platform market. mRNA technology emerged as a highly effective and rapid response to develop vaccines against the SARS-CoV-2 virus. The success of mRNA-based COVID-19 vaccines, such as those developed by Pfizer-BioNTech and Moderna, generated immense interest and investment in this segment. mRNA technology has demonstrated its versatility in the development of therapeutic vaccines for various diseases beyond infectious diseases. This includes cancer vaccines, where mRNA-based therapies aim to stimulate the immune system to target and destroy cancer cells, as well as vaccines for other diseases like influenza, Zika, and HIV. mRNA vaccines and therapeutic vaccines can be developed more rapidly than traditional vaccine platforms. This speed is especially valuable in responding to emerging infectious diseases and rapidly evolving pathogens.

mRNA Type Insights

In 2022, the Global mRNA Platform Market largest share was held by Self-Amplifying mRNA segment and is predicted to continue expanding over the coming years.  Self-amplifying mRNA (saRNA) technology is designed to produce higher levels of protein expression compared to conventional mRNA. This enhanced protein production capability can make saRNA particularly attractive for vaccine development and therapies targeting diseases that require a robust immune response. Self-amplifying mRNA can be engineered to carry genetic information for a wide range of antigens or therapeutic proteins. This versatility makes it a valuable tool for developing vaccines and therapies against various diseases, including infectious diseases and cancer. The development of advanced lipid nanoparticles (LNPs) for the delivery of self-amplifying mRNA has improved the stability and delivery efficiency of saRNA-based vaccines and therapies, further contributing to their market share.

End-User Insights

In 2022, the Global mRNA Platform Market largest share was held by Pharmaceutical Companies segment in the forecast period and is predicted to continue expanding over the coming years.  Pharmaceutical companies have a long history of conducting extensive research and development (R&D) in the field of drug discovery and development. They possess the scientific expertise, infrastructure, and financial resources required to advance mRNA-based therapies and vaccines. mRNA technology has shown immense promise for developing vaccines and therapeutics for a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders. Pharmaceutical companies have the experience and capabilities to bring these products from the research stage to clinical trials and ultimately to commercialization. Running clinical trials is a critical part of drug development. Pharmaceutical companies have the capacity to conduct large-scale clinical trials, which are necessary for gaining regulatory approvals and demonstrating the safety and efficacy of mRNA-based products.


Download Free Sample Report

Regional Insights

The North America region dominates the Global mRNA Platform Market in 2022. North America is home to some of the world's largest and most influential biotechnology and pharmaceutical companies, many of which have invested heavily in mRNA technology. Companies like Pfizer, Moderna, and BioNTech, which played pivotal roles in the development and commercialization of mRNA-based COVID-19 vaccines, are headquartered, or have a significant presence in North America. The region has a well-established and robust ecosystem for biomedical research and development. It boasts world-class universities, research institutions, and a highly skilled workforce dedicated to advancing mRNA technology. North America has attracted substantial investment and funding for mRNA research and development. Public and private funding agencies, venture capitalists, and government initiatives have supported the growth of mRNA-based therapies and vaccines.

Recent Developments

  • In April 2023, the inaugural face-to-face conference of the mRNA Technology Transfer Programme, hosted by WHO Director-General Tedros Adhanom Ghebreyesus, drew more than 200 delegates to Cape Town (South Africa). The mRNA technology hub facility at Afrigen Biologics and Vaccines (henceforth Afrigen; Cape Town, South Africa) was also inaugurated this past week. The scheme, which was introduced in 2021 as a reaction to the unequal access to the COVID-19 vaccine globally, is a partnership between WHO, Medicines Patent Pool, and corporate and public partners from 15 LMICs in Africa, Asia, Europe, and South America. Its goal was to provide LMICs the ability to independently design, produce, and distribute mRNA vaccines.    Afrigen, one of the partners, is in charge of the study, development, and transfer of mRNA vaccine platforms, with the South African Medical Research Council serving as sustainability coordinator. The pharmaceutical business Biovac (Cape Town, South Africa) will get the technology first before it is distributed to partners on other continents. Biovac will escalate manufacturing and distribution of the goods throughout the African partner countries.   
  • In June 2023, the first mRNA vaccine to be produced in India, GEMCOVAC-OM, was created by Gennova Image Courtesy Agencies utilising their own platform technology.

Key Market Players

  • AstraZeneca PLC
  • Asuragen, Inc.
  • Catalent Pharma Solutions
  • Arcturus Therapeutics, Inc.
  • BioNTech AG
  • CRISPR Therapeutics Inc.
  • AKESOgen, Inc.
  • baseclick GmbH
  • Accent Therapeutics Inc.
  • Accanis Biotech F&E GmbH & Co KG

By Indication

By Usability

By mRNA Type

By End-User

By Region

By Region
  • Autoimmune Diseases
  • Cancer
  • Infectious Diseases
  • Rare Diseases
  • Respiratory Diseases
  • Prophylactic Vaccines
  • Therapeutic Drugs
  • Therapeutic Vaccines
  • Nucleoside-Modified mRNA
  • Self-Amplifying mRNA
  • Unmodified mRNA
  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East

 

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     mRNA Platform Market, By Indication:

o   Autoimmune Diseases

o   Cancer

§  Personalized Treatment

§  Single Cancer Focussed

o   Infectious Diseases

o   Rare Diseases

o   Respiratory Diseases

  •     mRNA Platform Market, By Usability:

o   Prophylactic Vaccines

o   Therapeutic Drugs

o   Therapeutic Vaccines

  •   mRNA Platform Market, By mRNA Type:

o   Nucleoside-Modified mRNA

o   Self-Amplifying mRNA

o   Unmodified mRNA

  •     mRNA Platform Market, By End-User:

o   Hospitals & Clinics

o   Pharmaceutical Companies

o   Research Organization

  • Global mRNA Platform Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global mRNA Platform Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global mRNA Platform Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)

5.2.2.        By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)

5.2.3.        By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )

5.2.4.        By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)

5.2.5.        By Region

5.2.6.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific mRNA Platform Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Indication

6.2.2.        By Usability

6.2.3.        By mRNA Type

6.2.4.        By End User

6.2.5.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China mRNA Platform Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Indication

6.3.1.2.2.           By Usability

6.3.1.2.3.           By mRNA Type

6.3.1.2.4.           By End User

6.3.2.        India mRNA Platform Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Indication

6.3.2.2.2.           By Usability

6.3.2.2.3.           By mRNA Type

6.3.2.2.4.           By End User

6.3.3.        Australia mRNA Platform Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Indication

6.3.3.2.2.           By Usability

6.3.3.2.3.           By mRNA Type

6.3.3.2.4.           By End User

6.3.4.        Japan mRNA Platform Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Indication

6.3.4.2.2.           By Usability

6.3.4.2.3.           By mRNA Type

6.3.4.2.4.           By End User

6.3.5.        South Korea mRNA Platform Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Indication

6.3.5.2.2.           By Usability

6.3.5.2.3.           By mRNA Type

6.3.5.2.4.           By End User

7.    Europe mRNA Platform Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Indication

7.2.2.        By Usability

7.2.3.        By mRNA Type

7.2.4.        By End User

7.2.5.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France mRNA Platform Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Indication

7.3.1.2.2.           By Usability

7.3.1.2.3.           By mRNA Type

7.3.1.2.4.           By End User

7.3.2.        Germany mRNA Platform Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Indication

7.3.2.2.2.           By Usability

7.3.2.2.3.           By mRNA Type

7.3.2.2.4.           By End User

7.3.3.        Spain mRNA Platform Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Indication

7.3.3.2.2.           By Usability

7.3.3.2.3.           By mRNA Type

7.3.3.2.4.           By End User

7.3.4.        Italy mRNA Platform Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Indication

7.3.4.2.2.           By Usability

7.3.4.2.3.           By mRNA Type

7.3.4.2.4.           By End User

7.3.5.        United Kingdom mRNA Platform Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Indication

7.3.5.2.2.           By Usability

7.3.5.2.3.           By mRNA Type

7.3.5.2.4.           By End User

8.    North America mRNA Platform Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Indication

8.2.2.        By Usability

8.2.3.        By mRNA Type

8.2.4.        By End User

8.2.5.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States mRNA Platform Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Indication

8.3.1.2.2.           By Usability

8.3.1.2.3.           By mRNA Type

8.3.1.2.4.           By End User

8.3.2.        Mexico mRNA Platform Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Indication

8.3.2.2.2.           By Usability

8.3.2.2.3.           By mRNA Type

8.3.2.2.4.           By End User

8.3.3.        Canada mRNA Platform Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Indication

8.3.3.2.2.           By Usability

8.3.3.2.3.           By mRNA Type

8.3.3.2.4.           By End User

9.    South America mRNA Platform Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Indication

9.2.2.        By Usability

9.2.3.        By mRNA Type

9.2.4.        By End User

9.2.5.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil mRNA Platform Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Indication

9.3.1.2.2.           By Usability

9.3.1.2.3.           By mRNA Type

9.3.1.2.4.           By End User

9.3.2.        Argentina mRNA Platform Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Indication

9.3.2.2.2.           By Usability

9.3.2.2.3.           By mRNA Type

9.3.2.2.4.           By End User

9.3.3.        Colombia mRNA Platform Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Indication

9.3.3.2.2.           By Usability

9.3.3.2.3.           By mRNA Type

9.3.3.2.4.           By End User

10. Middle East and Africa mRNA Platform Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Indication

10.2.2.     By Usability

10.2.3.     By mRNA Type

10.2.4.     By End User

10.2.5.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa mRNA Platform Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Indication

10.3.1.2.2.         By Usability

10.3.1.2.3.         By mRNA Type

10.3.1.2.4.         By End User

10.3.2.     Saudi Arabia mRNA Platform Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Indication

10.3.2.2.2.         By Usability

10.3.2.2.3.         By mRNA Type

10.3.2.2.4.         By End User

10.3.3.     UAE mRNA Platform Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Indication

10.3.3.2.2.         By Usability

10.3.3.2.3.         By mRNA Type

10.3.3.2.4.         By End User

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Amgen Inc. AstraZeneca PLC

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Asuragen, Inc.

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Catalent Pharma Solutions

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   Arcturus Therapeutics, Inc.

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   BioNTech AG

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   CRISPR Therapeutics Inc.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   AKESOgen, Inc.

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   Baseclick GmbH

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   Accent Therapeutics Inc.

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.Accanis Biotech F&E GmbH & Co KG

16.10.1.  Business Overview

16.10.2.  Company Snapshot

16.10.3.  Products & Services

16.10.4.  Financials (In case of listed companies)

16.10.5.  Recent Developments

16.10.6.  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the MRNA Platform Market was estimated to be USD 7.30 billion in 2022.

down-arrow

AstraZeneca PLC, Arcturus Therapeutics, Inc. are some of the key players operating in the MRNA Platform Market.

down-arrow

Ensuring an adequate and stable supply of mRNA vaccines and therapies, especially during pandemics or global health emergencies, can be challenging.

down-arrow

The COVID-19 pandemic accelerated the adoption of mRNA technology for vaccine development.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

mRNA Platform Market to grow with a CAGR of 35.20%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global mRNA Platform Market.

Why Choose Us